Authors: Pitt B, Sutton NR, Wang Z, Holinstat M PMID: 33667455 PMCID: PMC7923868 DOI: 10.1016/j.ejphar.2021.173988 Abstract There is a need for therapeutic approaches to prevent and mitigate the effects of Coronavirus Disease (2019) (COVID-19). The histone deacetylase (HDAC) inhibitor valproic acid, which has been available for the therapy of epilepsy for many years, is a [...]

Authors: Logue JK, Franko NM, McCulloch DJ, McDonald D PMID: 33606031 PMCID: PMC7896197 DOI: 10.1001/jamanetworkopen.2021.0830 Abstract This cohort study analyzed persistent symptoms among adults with coronavirus disease 2019 up to 9 months after illness onset. Keywords: sequelae, COVID-19, Long COVID Source: https://pubmed.ncbi.nlm.nih.gov/33606031/ Archive: https://archive.is/ceI49

Authors: Luvanda M, Posch W, Vosper J, Zaderer V, Noureen A, Lass-Florl C PMID: 33498318 PMCID: PMC7909285 DOI: 10.3390/jof7020070 Abstract Since long-term corticosteroid treatment is associated with emerging opportunistic fungal infections causing high morbidity and mortality in immune-suppressed individuals, here we characterized the impact of dexamethasone (Dex) treatment on Aspergillus fumigatus-related immune modulation. We found [...]

Authors: Huang C, Huang L, Wang Y, Li X, Ren L, Gu X PMID: 33428867 PMCID: PMC7833295 DOI: 10.1016/S0140-6736(20)32656-8 Abstract Background: The long-term health consequences of COVID-19 remain largely unclear. The aim of this study was to describe the long-term health consequences of patients with COVID-19 who have been discharged from hospital and investigate [...]

PMID: 33555768 Abstract This guideline covers identifying, assessing and managing the long-term effects of COVID-19, often described as ‘long COVID’. It makes recommendations about care in all healthcare settings for adults, children and young people who have new or ongoing symptoms 4 weeks or more after the start of acute COVID-19. It also includes [...]

Authors: Franke C, Ferse C, Kreye J, Rocco A, Hosp J PMID: 33359380 PMCID: PMC7834471 DOI: 10.1016/j.bbi.2020.12.022 Abstract Background: COVID-19 intensive care patients can present with neurological syndromes, usually in the absence of SARS-CoV-2 in cerebrospinal fluid (CSF). The recent finding of some virus-neutralizing antibodies cross-reacting with brain tissue suggests the possible involvement of specific [...]

Authors: Yong SJ doi: https://doi.org/10.1080/23744235.2021.1924397 Abstract Long-haul COVID-19 illness first gained widespread recognition among social support groups and later in scientific and medical communities. This illness is mysterious as it affects COVID-19 survivors at all levels of disease severity, even younger adults and children. While the precise definition may be lacking, the defining symptoms are [...]

Authors: Chopra V, Flanders SA, O'Malley M PMID: 33175566 PMCID: PMC7707210 DOI: 10.7326/M20-5661 Abstract Background: Although characteristics and in-hospital outcomes for persons with coronavirus disease 2019 (COVID-19) have been well described, less is known about the longer-term outcomes of hospitalized patients. Objective: To describe 60-day postdischarge clinical, financial, and mental health outcomes of patients with [...]

Authors: Mandal S, Barnett J, Brill SE, Brown JS, Hare SS PMID: 33172844 PMCID: PMC7661378 DOI: 10.1136/thoraxjnl-2020-215818 Abstract Large numbers of people are being discharged from hospital following COVID-19 without assessment of recovery. In 384 patients (mean age 59.9 years; 62% male) followed a median 54 days post discharge, 53% reported persistent breathlessness, 34% cough [...]

Authors: Patterson BK, seethamraju H, Dhody K, Corley MJ, Kazempour K, Lalezari J et al. PMID: 33186704 PMCID: PMC7654230 DOI: 10.1016/j.ijid.2020.10.101 Abstract Objective: Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now a global pandemic. Emerging results indicate a dysregulated immune response. Given the role of CCR5 in immune cell migration and inflammation, [...]